None listed
Conditions
Interventions
Drug, Radiation : [Radiotherapy]
Total 44Gy (2.0Gy x 22 times_during 5 weeks)
GTV1: Gross disease (primary tumor + node metastasis)
CTV1: GTV1 + safety margin (cranio-caudal [YS1] 3-5 cm + circumfer
Sponsors
National Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - ECOG 0~2 - Good Organ Function (1) Absolute neutrophil count > 1500/mm3, platelets =100,000/mm3, Hemoglobin = 9g/dl (2) CCr = 20mL/min (Cockroft-Gautl)) (3) Total billrubin =1.5X UNL, AST /ALT =2.5X UNL - FEV1> 1.5L - Singed Informed Consesnt
Exclusion criteria
Exclusion criteria: 1. Have a history of esophageal Cancer who previously received topical therapy such as esophageal submucosal resection, surgery, radiation therapy or chemotherapy. 2. Have a distant metastasis lesion 3. Have a history of severe hypersenstivity to mannitol, paclitacxel, neoplatin or platinum based durg. 4. Have a hearing damage. 5. Have a hemorrhagic tumor 6. Have a additional malignancy is not disease free for more than 3 years. (except cured basal or smuamous skin cancer, cervial carcinoma in situ) 7. pregnant or breastfeeding 8. uncontrolled pychiatric disease, severy head injury, chronic alcoholism or drug addiction. CNS disease. 9 Have a weight loss of more than 10% during recent 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Best Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety evaluation | — |
Countries
Korea, Republic of
Contacts
Public ContactYoungJoo Lee
National Cancer Center
Outcome results
None listed